Sage Therapeutics Announces Positive Interim, Topline Data from Open-Label SHORELINE Study of Zuranolone in Patients with MDD
Sage Therapeutics announced interim, topline results from a July data cut of the ongoing Phase 3 open-label SHORELINE Study. This […]